NCT06003972View on ClinicalTrials.gov

Asses the Anti-inflammatory Effects of Short Term Copaxone Therapy on Patients the Acute Decompensated Heart Failure

PHASE2CompletedINTERVENTIONAL
Enrollment

14

Participants

Timeline

Start Date

January 4, 2021

Primary Completion Date

March 12, 2023

Study Completion Date

March 12, 2023

Conditions
Acute Decompensated Heart FailureCytokine StormInflammatory ResponseHeart Failure
Interventions
DRUG

Copaxone

Paptients allocated to this arm receive 20 mg GA given s.c daily for a total of 14 days

DRUG

guideline directed medical therapy (GDMT)

GDMT for heart failure according to the AHA guidelines.

Trial Locations (1)

911002

Hadassah Ein Kerem medical center-hospital ,Cardiology Department, Jerusalem

All Listed Sponsors
collaborator

Weizmann Institute of Science

OTHER

lead

Hadassah Medical Organization

OTHER

NCT06003972 - Asses the Anti-inflammatory Effects of Short Term Copaxone Therapy on Patients the Acute Decompensated Heart Failure | Biotech Hunter | Biotech Hunter